Stockreport

Arcutis After The Double: Hypergrowth Peaks, Compounding Remains [Seeking Alpha]

Arcutis Biotherapeutics, Inc. - Common stock  (ARQT) 
PDF ZORYVE approvals and revenue growth have driven a fair rerating, but forward expectations now imply slower compounding and less favorable risk/reward. ARQT's long-ter [Read more]